Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626338 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
A Phase 1 study, sponsored by Arog Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02626338: Completed Phase 1 study, sponsored by Arog Pharmaceuticals.
NCT02626338 is a Phase 1 study that has completed, run by Arog Pharmaceuticals. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02626338, a Phase 1 study, has completed, sponsored by Arog Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
Primary Outcome
To determine the response rate to crenolanib. Complete remission (CR) response criteria include a post-baseline bone marrow (BM) biopsy or aspiration % blasts \<5%, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L. CRi response included all CR criteria met, except participant did not have either platelet recovery or ANC recovery. CRh response included all CR criteria met, except subject only has partial platelet recovery and ANC recovery. Complete CR (CRc) response in
Interventions
- DRUG Fludarabine
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Mitoxantrone
- DRUG Crenolanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
What the finished NCT02626338 record still lists
NCT02626338 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT02626338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02626338 about?
NCT02626338 is a clinical study titled "Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML". The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
What is the current status of trial NCT02626338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-02. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02626338?
The interventions under investigation include: Fludarabine (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Mitoxantrone (DRUG), Crenolanib (DRUG).
Who is sponsoring clinical trial NCT02626338?
This trial is sponsored by Arog Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02626338's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia